PNV - Banter and General Comments, page-7606

Having a look at what BTM sales revenue we could expect with back of the napkin maths, *Excludes BARDA income

H1 FY 21/22, BTM sales were $16.27M, up 44.6% on the previous period.

H2 FY 20/21 BTM sales were $14.25M, up 31% on the previous period.

FY 21/22 Full year BTM sales is hence $16.27M + ($14.25M multiplied by x%)

As a lower bound BTM sales figure for H2 FY 21/22, 31% growth is used, assumig pretty terrible hospital access and high covid hospitalisations.
This gives a figure of $18.66M for the half and total Yearly sales of ~$34.93M. This scenario is highly unrealistic.

If BTM sales were to have grown at the same rate as in H1 of the Financial year, H2 BTM sales would be $20.52M. This gives Full year BTM sales of $36.79M. I would consider this a unlikely outcome, seeing as new employees from last year would be much more accustomed to the product and sales aspect of BTM. Then there are new recruits who will add a little extra, as they get up and running.

Using a growth rate of 60%, based on more employees, new contracts, better trained employees and a favourable USDAUD FOREX rate. This gives H2 BTM sales of $22.8M, giving FY21/22 gross sales of $39.07M. This equates to 57.6% increase in sales for FY21/22 as compared to last FY.

In my opinion, circa $40M is an expected BTM sales target

For great BTM sales results in the realm of $42M, 80% growth is needed for the H2 as compared to H2 of the previous year.

Are there any arguments regarding if its realistically feasible for PNV to publish 80% Half on Half growth in these economic conditions?